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In 2015, 10.4 million people developed 
tuberculosis (TB) and 580,000 amongst them 
suffered from multidrug-resistant TB (MDR-
TB). From those 580,000 cases of MDR-TB, 
only 125,000 were detected and reported.1 A 
total of 111,000 people began to receive MDR-
TB treatment in 2014 while 190,000 MDR-TB 
patients were estimated to have died, largely 
due to lack of access to effective treatment.2 The 
mechanism of drug resistance can be caused 
by genetic factors, factors related to previous 
treatment and other factors such as comorbidity 
with diabetes mellitus.3,4 Although there is 
some evidence which postulate host genetic 
predisposition is the basis for the development 
of MDR-TB, changes in the genomic content is 
the major underlying event in the emergence of 
variants strains in the M. tuberculosis complex. 
Spontaneous chromosomally-borne mutation 
occurring in M. tuberculosis at predictable rates 
are thought to confer resistance to anti-TB drugs.3 
Factors related to previous anti-tuberculosis 
treatments consists of incomplete or inadequate 
treatment and also poor treatment adherence. A 
review of the published literature strongly suggest 
that the most powerful predictor for the presence 
of MDR-TB is a history of TB treatment. Many 
new cases of MDR-TB are created by physician’s 
errors related to drugs regimen, dosing interval 
and duration of treatment. Multidrug-resistance 
TB developed due to error in TB management 
in the past such as initiation of an inadequat 
regimen using first line anti-TB drugs, the 
addition of single drug to a failing regimen, the 
failure to identify pre-existing resistance and 
variations in bioavailability of anti-TB drugs 
that predispose the patient to the development 
of MDR-TB. Non-adherence to prescribed 
treatment is often underestimated by physicians 
and difficult to predict.3-8 Certain factors such as 
psychiatric illness, alcoholism, drug additiction 
and homelessness can predict non-adherence to 
treatment. Poor compliance with the treatment 
is also an important factor in the development of 
acquired drug resistance.3
Diabetes mellitus has been a well-known risk 
factor for TB in the past. The global convergence 
of the accelerating type 2 DM pandemic, high 
TB prevalence and drug-resistant TB during the 
past couple of decades has become a serious 
challenge to clinicians worldwide. Over the past 
few years, some studies have shown that the 
treatment failure rate is higher in TB patients 
with DM as comorbidity. Moreover, there is 
significant association between DM an MDR-
TB.4,9 There is higher chance of TB bacilli 
persistence to be present in sputum of pulmonary 
TB patient with DM than TB-only patient after 
5 months treatment, and this persistence made 
it necessary for more longer treatment. Presence 
of DM in TB patients cause a longer period for 
sputum conversion, therefore it may become a 
major cause of poor treatment outcome in TB 
patients. Previous studies showed that a major 
mechanism for the emergence of drugs resistance 
in TB bacilli is random mutation in the bacterial 
genome and the pressure of selection by anti-TB 
drugs. Pulmonary TB in diabetic patients usually 
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show higher mycobacterial loads at the initiation 
of treatment, hence they may have higher chance 
of bacillary mutation and the emergence of MDR-
TB with the presenting of higher bacterial loads, 
longer treatment is needed to clear the bacteria. 
Therefore, it is not suprising that a higher chance 
of MDR-TB patients could be find in those 
patients.9 A pharmacokinetic study noted that 
plasma levels of rifampicin were 53% lower in 
TB patients with diabetes, which might affect 
treatment outcomes.10 Inadequate immune respons 
of the host may also be important in this negative 
effect of diabetes. Depressed production of 
IFN-γ in diabetic patients is related to decreasing 
immune response to TB infection. Reduction of 
IL-12 response to mycobacterial stimulation in 
leukocytes from TB with diabetic patients suggest 
a compromise of innate immune response.9
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